Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index; 50 of the 77 sources its claims cite were checked for support.

Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications

Open access
Goulian, Andrew J., Goldstein, Brielle, Saad, Maarouf A. · 2025 · Journal of Clinical Medicine

Abstract

Background/Objectives: Regenerative therapies have gained interest in orthopedic applications for their potential to enhance tissue regeneration, functional recovery, and pain modification. This review evaluates the clinical efficacy of platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), peptide-based treatments, and biomimetic materials in orthopedic care, with a focus on pain reduction and functional outcomes. Methods: A structured literature search in PubMed (January 2009–January 2025) identified 160 studies. After applying inclusion criteria prioritizing randomized controlled trials (RCTs) and clinical trials, 59 studies were included: 20 on PRP, 20 on MSCs, 10 on peptide therapies, and 7 on biomimetics. Data extraction focused on pain reduction and functional recovery, with risk of bias assessed using the Cochrane Risk of Bias (RoB) tool and ROBINS-I tool. A random-effects meta-regression analysis was conducted to evaluate the impact of therapy type, sample size, and risk of bias on reported pain reduction outcomes. Results: Meta-regression analysis identified MSC therapy as the most effective intervention for pain reduction (β = 8.45, p < 0.05), with PRP and peptide-based therapies showing moderate improvements, and biomimetic therapies demonstrating the lowest effect. PRP provided short-term pain relief, particularly in acute injuries and tendon repair, though inconsistencies in preparation methods limited success in chronic conditions. MSC therapies demonstrated cartilage regeneration and early osteoarthritis improvement, but high costs and ethical concerns remain barriers to widespread adoption. Peptide-based therapies and biomimetic materials, including engineered scaffolds and autologous protein solutions, showed promise for infection control and wound healing, though further research is needed to optimize dosing, delivery methods, and long-term safety. Conclusions: Regenerative therapies offer significant potential in orthopedic care, with MSC therapies demonstrating the most reliable regenerative effects, PRP providing short-term symptomatic relief, and peptide-based and biomimetic treatments emerging as promising adjuncts. However, standardized protocols and large-scale clinical trials are needed to establish long-term efficacy and improve clinical translation for broader adoption.

Overview

CoChat Summary

TL;DR

This review compares clinical evidence for PRP, mesenchymal stem cells (MSCs), peptide therapies, and biomimetic materials in orthopedic care, focusing on pain reduction and functional recovery. Across 59 included studies, MSCs showed the strongest pain-reduction signal, while PRP tended to provide short-term relief and peptide/biomimetic approaches remained promising but less established.

Key findings

  • The PubMed search (January 2009–January 2025) identified 160 studies, and 59 studies met inclusion criteria: 20 PRP, 20 MSC, 10 peptide, and 7 biomimetic studies.
  • Mean reported pain reduction was highest for MSC therapy (45.05 ± 3.85%), followed by PRP (41.00 ± 6.36%), biomimetic therapies (37.43 ± 2.82%), and peptide therapies (35.50 ± 3.03%).
  • Welch’s ANOVA showed a significant difference in pain reduction across therapy types (F(3, 43) = 13.31, p < 0.001). Games–Howell tests found stem cell therapy had significantly greater pain reduction than peptides, PRP, and biomimetics (all p < 0.001).
  • Meta-regression found therapy type significantly influenced pain reduction (QM(df = 3) = 14.15, p < 0.05); sample size and risk of bias were not significant predictors, and residual heterogeneity remained high (I² = 81.13%).

Methods

  • This was a comprehensive review of clinical orthopedic studies on PRP, MSCs, peptide therapies, and biomimetic materials, using a PRISMA-guided PubMed search from January 2009 to January 2025.
  • Inclusion prioritized clinical trials and randomized controlled trials; studies had to report orthopedic outcomes such as pain reduction, functional recovery, infection rates, healing time, or quality-of-life measures. Preclinical, non-English, or otherwise ineligible studies were excluded.
  • Risk of bias was assessed with the Cochrane RoB tool and ROBINS-I. The authors then conducted a random-effects meta-regression (REML) plus one-way ANOVA/Welch’s ANOVA and Games–Howell post hoc tests in R 4.4.2.

Limitations

  • The paper states that 10 studies were omitted from the pain-reduction analysis because that outcome was missing or unreported; it notes this was most common in PRP studies.
  • The review reports substantial residual heterogeneity (I² = 81.13%), meaning important study-level factors likely remained unmeasured.
  • Many included studies were single-center with small sample sizes, limiting generalizability; the paper also notes heterogeneity in PRP preparation, MSC sourcing, and peptide dosing, and limited long-term follow-up.
  • Evident from the text: the quantitative synthesis focused on pain reduction, so conclusions about broader outcomes like function, durability, or safety are less directly supported by the pooled analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jcm14062061

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Visual overview of regenerative therapies in orthopedics. Created with BioRender.com (accessed 27 January 2025).
Figure 1 Visual overview of regenerative therapies in orthopedics. Created with BioRender.com (accessed 27 January 2025).CC BY · PubMed Central
Figure 2 PRISMA flow diagram of study selection process. Created with BioRender.com (accessed on 27 January 2025).
Figure 2 PRISMA flow diagram of study selection process. Created with BioRender.com (accessed on 27 January 2025).CC BY · PubMed Central
Figure 3 Forest plot of meta-regression results evaluating the impact of therapy type, sample size, and risk of bias on pain reduction outcomes. The confidence intervals (CIs) represent the estimated range within which the true effect sizes are likely to fall. The dashed vertical line at zero represents the baseline effect of the reference category (biomimetic therapies). Green indicates statistically significant effects, while blue represents non-significant findings.
Figure 3 Forest plot of meta-regression results evaluating the impact of therapy type, sample size, and risk of bias on pain reduction outcomes. The confidence intervals (CIs) represent the estimated range within which the true effect sizes are likely to fall. The dashed vertical line at zero represents the baseline effect of the reference category (biomimetic therapies). Green indicates statistically significant effects, while blue represents non-significant findings.CC BY · PubMed Central

Verification

Claims the paper makes

33 Valid · 9 Not valid · 16 Not checked · 58 Own results and interpretations

62 more claims · 13 with their cited sources checked

Create a free account to see all 116 claims and to verify the 11 references still open.

See all claims — free account
  • It may state two separate claims as one. 47
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • ConsistentF(3, 43) = 3.64reported p < .05 · recomputed p = .020

    “F(3, 43) = 3.64, p < .05”

  • ConsistentF(3, 43) = 13.31reported p < .001 · recomputed p < .001

    “F(3, 43) = 13.31, p < .001”

2 of 2

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 136 references

Research works printed but not linked: 1

  1. Chaudhary, 2024, Emerging trends in PRP and MSC-based therapies: A review of clinical efficacy and limitations, Int. J. Musculoskelet. Med., 12, 85

Cited by

See all 25

Metadata

Authors
Goulian, A. J., Goldstein, B., & Saad, M. A.
Affiliations
  • California Northstate University (US)
  • Department of Orthopaedic Surgery, University of California, Sacramento, CA 95817, USA
Corresponding author
Saad, Maarouf A.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2025-03-18
Volume
14
Issue
6
Pages
2061
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4408551393
Cited by
25
References
136
Citations by year
2026: 14 · 2025: 11
FWCI
5.19
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Tendon Structure and Treatment
Keywords
regenerative therapy, orthopedics, platelet-rich plasma, mesenchymal stem cells, peptide therapy, biomimetic materials, analgesia, functional recovery, cartilage regeneration, osteoarthritis, engineered scaffolds, wound healing, infection control, tendon repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications. https://app.cochat.ai/papers/10.3390/jcm14062061
The paper
Goulian, A. J., Goldstein, B., & Saad, M. A. (2025). Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14062061

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.